All Updates

All Updates

icon
Filter
Funding
Oniria Therapeutics raises EUR 1.3 million in seed funding
Precision Medicine
May 11, 2023
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Funding
OceanWell raises USD 11 million in Series A funding to build water farms
Conservation Tech
Yesterday
Product updates
H launches Runner H, an AI agent for business automation
Foundation Models
Yesterday
Partnerships
Capgemini partners with Mistral AI and Microsoft to expand GenAI solutions globally
Foundation Models
Yesterday
Funding
Product updates
Converge Bio launches biotech LLM platform with USD 5.5 million seed funding
Foundation Models
Yesterday
Partnerships
Snowflake partners with Anthropic to integrate Claude AI models into Cortex AI platform
Foundation Models
Yesterday
Product updates
DeepSeek releases AI reasoning model DeepSeek-R1
Foundation Models
Yesterday
Industry news
Partnerships
ICEYE partners with Lockheed Martin and Finnish firms to develop defense space technologies
Next-gen Satellites
Yesterday
Partnerships
Dematic installs AutoStore system at South West Healthcare logistics hub
Logistics Tech
Yesterday
Precision Medicine

Precision Medicine

May 11, 2023

Oniria Therapeutics raises EUR 1.3 million in seed funding

Funding

  • Spain-based drug discovery company Oniria Therapeutics has raised EUR 1.28 million (USD 1.4 million) in a seed funding round led by Mind the Gap, a biotech entrepreneurship program, with participation from BStartup of Banco Sabadell, angel investors, and public funding.

  • The funding will be used to enhance the development of its lead drug candidate, ONR-001, which is designed to eliminate persistent tumor cells that remain after traditional treatments. 

  • Oniria Therapeutics is developing precision oncology therapies focused on eliminating persistent tumor cells that are responsible for cancer progression. Its lead and only drug candidate, ONR-001, is a first-in-class molecule that activates TET2, an epigenetic enzyme, inducing a dormant state in tumor cells and has the potential to lead to their death. This approach can be applied at various stages of the disease, ranging from early primary tumors to recurrent metastatic cancer that is resistant to treatment. The company was established in 2021 as a spinoff from the Vall d'Hebron Institute of Oncology, the University of Barcelona, and the Catalan Institution for Research and Advanced Studies.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.